Literature DB >> 16896577

Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.

R B Podlasin1, A Wiercinska-Drapalo, A Olczak, M Beniowski, T Smiatacz, E Malolepsza, J Juszczyk, M Leszczyszyn-Pynka, T Mach, M Mian, B Knysz, A Horban.   

Abstract

BACKGROUND: The introduction of highly active antiretroviral therapy (HAART) led to a decreased incidence of the most severe opportunistic infections (OIs) in HIV-infected patients. In Poland, HAART became widely used in 1998.
MATERIALS AND METHODS: This study was based on data from medical records data collected in the years 2000-2002 from medical centers for HIV-infected patients in Poland. The aim of the study was to determine the incidence of opportunistic infections (OIs) and other AIDS defining illnesses (ADIs). The chi(2) test was used to determine any significant trends.
RESULTS: The incidence of ADIs was 6.8, 6.5 and 4.8/100 persons/year in 2000-2002, respectively. The most common diagnosed OIs were: fungal infections, tuberculosis, recurrent pneumonia, PCP and toxoplasmosis. In patients receiving HAART (HAART+) the incidence of ADIs was significantly lower than in non-ARV-treated as well as in all HIV+ (p < 0.02, p < 0.001, p < 0.001, respectively). A significant decrease in the incidence of ADIs in HAART+ patients between 2000 and 2002 (p < 0.0001) was observed. From 25% to 30% of ADIs among HAART+ patients were diagnosed within the first 3 months of antiretroviral therapy. In HAART+ patients the most common ADIs were fungal infections and tuberculosis. The diagnosis of ADIs resulted in the recognition of HIV status in 8.7-8.9% of patients.
CONCLUSIONS: Five years after the introduction of HAART the incidence of ADIs had declined. Fungal infections and tuberculosis were the most common OIs in HIV+ patients in Poland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896577     DOI: 10.1007/s15010-006-5030-y

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Toxoplasma gondii infection in hospitalized people living with HIV in Spain, 1997 to 2015.

Authors:  Marouane Menchi-Elanzi; Asunción M Mayoral; Javier Morales; Hector Pinargote-Celorio; Gregorio González-Alcaide; José-Manuel Ramos-Rincón
Journal:  Parasitol Res       Date:  2021-01-14       Impact factor: 2.289

2.  Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil.

Authors:  Lara Coelho; Sandra Wagner Cardoso; Rodrigo Teixeira Amancio; Ronaldo Ismério Moreira; Dayse Pereira Campos; Valdiléa Gonçalves Veloso; Beatriz Grinsztejn; Paula Mendes Luz
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

3.  Changing Spectrum of Opportunistic Illnesses among HIV-Infected Taiwanese Patients in Response to a 10-Year National Anti-TB Programme.

Authors:  Chun-Yuan Lee; Pei-Hua Wu; Po-Liang Lu; Hung-Chin Tsai
Journal:  J Clin Med       Date:  2019-02-01       Impact factor: 4.241

4.  Incidence and predictors of HIV related opportunistic infections after initiation of highly active antiretroviral therapy at Ayder Referral Hospital, Mekelle, Ethiopia: A retrospective single centered cohort study.

Authors:  Zekarias Gessesse Arefaine; Sintayehu Abebe; Ephrem Bekele; Amir Adem; Yohannes Adama; Norbert H Brockmeyer; Judith Coenenberg; Anja Potthoff; Teferi Gebru Gebremeskel
Journal:  PLoS One       Date:  2020-04-20       Impact factor: 3.240

5.  Seronegative Infection with Toxoplasma gondii in Asymptomatic Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Patients and in Blood Donors.

Authors:  Agnieszka Pawełczyk; Małgorzata Bednarska; Kamila Caraballo Cortés; Marianna Glamkowska-Sady; Justyna Kowalska; Beata Uszyńska-Kałuża; Marek Radkowski; Renata Welc-Falęciak
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

Review 6.  Trends in overall opportunistic illnesses, Pneumocystis carinii pneumonia, cerebral toxoplasmosis and Mycobacterium avium complex incidence rates over the 30 years of the HIV epidemic: a systematic review.

Authors:  Lara Coelho; Valdiléa Gonçalves Veloso; Beatriz Grinsztejn; Paula Mendes Luz
Journal:  Braz J Infect Dis       Date:  2013-11-23       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.